Mallinckrodt plc: Mallinckrodt Presents Data on Real-World Outcomes with THERAKOS CELLEX Photopheresis System Treatment at the 2024 Tandem Meetings finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Mallinckrodt Announces Publication of Real-World Data on the Use of Extracorporeal Photopheresis (ECP) in Heart Transplant Patients vietreader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from vietreader.com Daily Mail and Mail on Sunday newspapers.
Mallinckrodt plc (NYSE American: MNK), a global specialty pharmaceutical company, today announced the publication of findings from a retrospective, observational, single arm, European chart review study assessing the real-world use of extracorporeal photopheresis (ECP) and its impact on clinical outcomes in the modern era of heart transplantation.1 An online version of the data manuscript – the largest-known study of ECP in heart transplant patients – is currently published on the Journal of Hea
- Results from the largest European and first multicenter, retrospective, observational chart review study investigating the real-world use of ECP in heart transplant patients reinforce its
Sanofi Genzyme: Neurodermitis Familiensache - lasst uns darüber reden! : 4 Internationaler Neurodermitis Tag steht im Zeichen der Familie - ots Presseportal - Advertorials tagesspiegel.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tagesspiegel.de Daily Mail and Mail on Sunday newspapers.